Multiple Sclerosis Presenting as Lower Motor Neuron Wasting and Weakness of the Distal Upper Extremity
Neurol 61:1303-1304, Chong,P.S.T.,et al, 2003
Peripheral Nervous System Involvement in Multiple Sclerosis
Neurol 41:457-460, Zee,P.C.,et al, 1991
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
"Better Explanations" in Multiple Sclerosis Diagnostic Workup
Neurol 92:e2527-e2537, Calabrese, M.,et al, 2019
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014
Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012
Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential: Follow-Up of 70 Patients
Arch Neurol 66:841-846, Lebrun,C.,et al, 2009
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Vagal Nerve Stimulation Effect on Cerebellar Tremor in Multiple Sclerosis
Neurol 65:499, Marrosu,F.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
Ann Neurol 50:121-127, McDonald,W.I.,et al, 2001
Practice Parameter: The Usefulness of Evoked Potentials in Identifying Clinically Silent Lesions in Patients With Suspected Multiple Sclerosis (an Evidence-Based Review)
Neurol 54:1720-1725, Gronseth,G.S.&Ashman,E.J., 2000
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Assessment of Olfaction in Multiple Sclerosis:Evidence of Dysfunction by Olfactory Evoked Response and Identification Tests
JNNP 63:145-151, Hawkes,C.H.,et al, 1997
Tizanidine for Spasticity
The Medical Letter 39:62, , 1997
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Clinical and Subclinical Neurological Involvement in Children of Conjugal Multiple Sclerosis Patients
Multiple Sclerosis 1:170-172, Constantinescu,C.S.,et al, 1996
Palliative Care in Neurology
Neurol 46:870-872, 5981996., Bernat,J.L.,et al, 1996
Is Chronic Respiratory Failure in Neuromuscular Diseases Worth Treating
JNNP 61:1-3, Shneerson,J.M., 1996
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
A Randomized Trial of Test Result Sequencing in Patients with Suspected Multiple Sclerosis
Arch Neurol 51:53-59, O'Connor,P.,et al, 1994
Tizanidine Treatment of Spasticity Caused by Multiple Sclerosis:Results of a Double-Blinded, Placebo-Controlled Trial
Neurol 44:S34-S43, Smith,C.,et al, 1994
A Double-Blind, Placebo-Controlled Trial of Tizanidine in the Treatment of Spasticity Caused by Multiple Sclerosis
Neurol 44:S70-S78, Barnes,M.P.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Sudden Hearing Loss as the Initial Monosymptom of Multiple Sclerosis
Neurol 43:2703-2705, Drulovic,B.,et al, 1993
Event-Related Potential P300 in MS, Relation to Magnetic Resonance Imaging and Cognitive Impairment
Arch Neurol 49:44-50, Honig,L.S.,et al, 1992
Frequent Involvement of the Optic Radiation in Patients with Acute Isolated Optic Neuritis
Neurol 42:77-79, Hornabrook,R.S.L.,et al, 1992
Symptomatic Retrochiasmal Lesions in MS:Clinical Features, Visual Evoked Potentials, and Magnetic Resonanc Imaging
Neurol 42:68-76, Plant,G.T.,et al, 1992
Surgical Treatment of Cervical Spondylotic Myelopathy:Time for a Controlled Trial
Neurol 42:5-13, Rowland,L.P., 1992
"Fatigue"in Patients with Multiple Sclerosis
Arch Neurol 49:517-524, Sandroni,P.,et al, 1992
The Diagnostic Reliability of Magnetically Evoked Motor Potentials In Multiple Sclerosis
Neurol 42:1296-1301, Ravnborg,M.,et al, 1992
Lidocaine Unmasks Silent Demyelinative Lesions in Multiple Sclerosis
Neurol 42:2088-2093, Sakurai,M.,et al, 1992
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Glutethimide Treatment of Disabling Action Tremor in Patients with MS and Traumatic Brain Injury
Arch Neurol 48:513-515, Aisen,M.L.,et al, 1991